Literature DB >> 27786097

The effects of vasoactive intestinal peptide in neurodegenerative disorders.

Guangxiu Deng1, Lan Jin1.   

Abstract

Neurodegenerative disorders (NDDs) are characterized by neuronal death in the brain. The mechanism of the neuronal death is too complicated to be fully understood, although in many NDDs, aging and neurotoxins are known risk factors. In the central and peripheral nervous system, vasoactive intestinal peptide (VIP), a 28-amino acid neuropeptide, is released to support neuronal survival in both physiological and pathological condition. VIP can inhibit the neurodegeneration induced by the loss of neurons. The indirect protection effect is mainly mediated by glial cells through the production of neurotrophic factor(s) and inhibition of proinflammatory mediators. By remolding the structure and improving the transfer efficiency of VIP, its nerve protective function could be further improved. Its neuroprotective action and efficacy in inhibiting a broad range of inflammatory responses make VIP or related peptides becoming a novel therapeutic method to NDDs. In this review, we aim to summarize the relationship between VIP and NDDs.

Entities:  

Keywords:  NDDs; VIP; inflammation; neuroprotection; neurotrophin

Mesh:

Substances:

Year:  2016        PMID: 27786097     DOI: 10.1080/01616412.2016.1250458

Source DB:  PubMed          Journal:  Neurol Res        ISSN: 0161-6412            Impact factor:   2.448


  18 in total

1.  Vasoactive Intestinal Peptide Decreases β-Amyloid Accumulation and Prevents Brain Atrophy in the 5xFAD Mouse Model of Alzheimer's Disease.

Authors:  Orhan Tansel Korkmaz; Hakan Ay; Nurgul Aytan; Isabel Carreras; Neil W Kowall; Alpaslan Dedeoglu; Nese Tuncel
Journal:  J Mol Neurosci       Date:  2018-11-29       Impact factor: 3.444

2.  Effect of castration on pelvic neurons in the male pig.

Authors:  Jerzy Kaleczyc; Natalia Kasica-Jarosz; Zenon Pidsudko; Agnieszka Dudek; Magdalena Klimczuk; Waldemar Sienkiewicz
Journal:  Histochem Cell Biol       Date:  2020-01-01       Impact factor: 4.304

Review 3.  Pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal peptide (Part 2): biology and clinical importance in central nervous system and inflammatory disorders.

Authors:  Terry W Moody; Robert T Jensen
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2021-04-01       Impact factor: 3.626

Review 4.  Pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal peptide [Part 1]: biology, pharmacology, and new insights into their cellular basis of action/signaling which are providing new therapeutic targets.

Authors:  Terry W Moody; Robert T Jensen
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2021-04-01       Impact factor: 3.626

5.  Age-Related Gene Expression in the Frontal Cortex Suggests Synaptic Function Changes in Specific Inhibitory Neuron Subtypes.

Authors:  Leon French; TianZhou Ma; Hyunjung Oh; George C Tseng; Etienne Sibille
Journal:  Front Aging Neurosci       Date:  2017-05-29       Impact factor: 5.750

Review 6.  Vasoactive Intestinal Polypeptide in the Carotid Body-A History of Forty Years of Research. A Mini Review.

Authors:  Slawomir Gonkowski
Journal:  Int J Mol Sci       Date:  2020-06-30       Impact factor: 5.923

Review 7.  VIP Modulation of Hippocampal Synaptic Plasticity: A Role for VIP Receptors as Therapeutic Targets in Cognitive Decline and Mesial Temporal Lobe Epilepsy.

Authors:  Diana Cunha-Reis; Ana Caulino-Rocha
Journal:  Front Cell Neurosci       Date:  2020-06-12       Impact factor: 5.505

8.  Octreotide reverses shock due to vasoactive intestinal peptide-secreting adrenal pheochromocytoma: A case report and review of literature.

Authors:  Xiao Hu; Wei Cao; Min Zhao
Journal:  World J Clin Cases       Date:  2018-11-26       Impact factor: 1.337

9.  A Synthetic Agonist to Vasoactive Intestinal Peptide Receptor-2 Induces Regulatory T Cell Neuroprotective Activities in Models of Parkinson's Disease.

Authors:  R Lee Mosley; Yaman Lu; Katherine E Olson; Jatin Machhi; Wenhui Yan; Krista L Namminga; Jenell R Smith; Scott J Shandler; Howard E Gendelman
Journal:  Front Cell Neurosci       Date:  2019-09-18       Impact factor: 5.505

10.  Recombinant expressed vasoactive intestinal peptide analogue ameliorates TNBS-induced colitis in rats.

Authors:  Chun-Lan Xu; Yu Guo; Lei Qiao; Li Ma; Yi-Yi Cheng
Journal:  World J Gastroenterol       Date:  2018-02-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.